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approachAbstract A series of 7-chloro-4-[4-(substituted arylideneimino)] 2,5-dioxo-1,4 piperazinoquinoline
VI was designed by molecular hybridization approach and synthesized for biological evaluation.
Virtual screening was carried out through docking the designed compounds into the ATP binding
site of epidermal growth factor receptor (EGFR) to predict if these compounds have similar binding
mode as the EGFR inhibitors. Subsequently, the compounds were examined for their cytotoxic
effect on human breast cell-line (MCF-7) in which the EGFR is highly expressed. Although most
of the compounds were quite effective on the breast cancer cell line examined, the compounds II,
III, IVa, IVc, VIa, VIc emerged as the most active among the prepared series. Thus 7-chloro-4-
[4-(substitutedarylideneimino) 2,5-dioxo-1,4 piperazinoquinoline can serve as the prototype mole-
cule for further development of a new class of EGFR Tyrosine Kinase inhibitors and anti-breast
cancer agents.
ª 2011 Faculty of Pharmacy, Cairo University. Production and hosting by Elsevier B.V.
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The growing incidence of drug resistance to cancer chemother-
apeutic agents represents a serious medical problem.1 There-
fore there is an urgent need to develop new classes of
chemotherapeutic agents to treat cancer.2 A combinational
chemotherapeutic drug with different mechanisms of action
is one of the methods that are being adopted to treat can-
cer.3–6 Besides the exploitation of new targets, there is another
approach combining two or more pharmacophores into a sin-
gle molecule. Therefore a single molecule containing more than
one pharmacophore, each with different mode of action, could
Figure 3 Concentration of II in lg/ml.
60 E.I. Alybe beneﬁcial for the treatment of cancer.7–9 These merged
pharmacophores may be addressing the active site of different
targets and offer the possibility to overcome drug resistance. In
addition, this approach can also reduce unwanted side ef-
fects.3,4,6,7 The success of this hybridization approach has al-
ready been applied in developing novel antibacterial and
antimalarial agents to overcome drug resistance.9–13
Recently it has been demonstrated that 10 lM chloroquine
(Fig. 1 CQ) signiﬁcantly increases cancer cell killing
effects.3,4,14 Although the antineoplastic activity of these quin-
olines was attributed to intercalating binding to DNA, there
were additional advantages in quinolines that interact with
DNA, with low association constant. The corresponding sig-
niﬁcant increase in the amount of free drug at equilibrium
may have an important effect upon distribution and hence
the spectrum of activity and accessibility of these molecules
to solid tumor.15,16 In addition a number of quinoline deriva-
tives were reported to reverse tumor cell multidrug resis-
tance.17,18 Several CQ analogs (Figs. 1–3) have been
synthesized and examined as cytotoxic agents against (MCF-
7) breast cancer cell line. Some of these compounds were very
effective.19 The lysosomotropic CQ accumulated in the
lysosomes, raises intra-lysosomal pH, and interferes with
auto-phagosome degradation in the lysosomes. This unique
property of CQ and its analogs may be important for the
enhancement of cell killing by cancer therapeutic agents in a
variety of different tumors.20 Published data showed that the
piperazinoquinoline pharmacophore is one of the most effec-
tive newly emerging class of heterocyclic molecules that pos-
sessed antitumor activity21,22 (Figs. 2, 4 and 5). In additionN
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Figure 1 Chemical structure of 4-aminoqumany researches proved the importance of azomethine link
or Schiff bases in anticancer drug.23,24
The present work is an effort toward developing effective
anticancer agents by a hybrid pharmacophore approach using
the 4-piperazinyl-quinoline scaffold. There are accumulating
lines of evidence that hybridization of two or more bioactiveN
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Figure 4 Concentration of III in lg/ml.
Figure 5 Concentration of VIa in lg/ml.
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with different mechanisms of action often render synergistic
effects.8–13 Encouraged by these previous reports we designed
different set of compounds (Scheme 1) by hybridizing two or
more different pharmacophores (7-chloroquinolines, azome-
thine, piperazinedione) in the aim of prospecting their anti-
breast cancer potentiality.
2. Chemistry
Compounds (II–VI) described in this study were synthesized as
outlined in Scheme 1. 4,7-Dichloroquinoline I was reacted with
glycine ethyl ester to afford compound II which upon reaction
with hydrazine hydrate produced the key compound III. The
target compounds VIa–e were obtained through two differentpathways. The ﬁrst includes the reaction of compound III with
different aromatic aldehydes to yield Shiff’s base IVa–f which
upon cyclization with chloroacetylchloride afforded the de-
sired compounds VIa–e. Alternatively, the second pathway in-
volves primarily cyclization of the key compound III via
reaction with chloroacetylchloride to produce compound V
which through interaction with different aromatic aldehydes
ends into our target compounds.3. Materials and methods
3.1. Experimental
Melting points were determined with a Gallenkamp (London,
UK) melting point apparatus and are uncorrected. IR spectra
(KBr, cm1) were recorded on Bruker Vector, 22 FT-IR
(Fourier Transform Infrared – FT-IR) (Germany) spectrome-
ter. 1H NMR spectra were recorded on a Varian Gemini-200
(200-MHz, Foster City Calif., USA) and Varian Mercury-300
(300-MHz, City: Palo Alto, State: Calif., USA spectrometers
using dimethyl sulfoxide (DMSO)-d6 as a solvent and tetra-
methylsilane (TMS) as an internal standard (Chemical shift
in d, ppm). Mass spectra were determined using Mass spec-
trometers GC/MS Shimadzu QP 1000 EX (Shimadzu Corpora-
tion, Tokyo, Japan) with ionization energy 70 eV. Elemental
analyses were determined using Automatic Elemental Analyzer
CHN Model 2400 Perkin-Elmer (USA) at Microanalytical
Center, Faculty of Science, Cairo University, Egypt. All the
results of elemental analyses corresponded to the calculated
values within experimental error. Progress of the reaction was
monitored by thin-layer chromatography (TLC) using pre-
coated TLC sheets with Ultraviolet (UV) ﬂuorescent silica gel
(Merck 60F254) and spots were visualized by iodine vapors
or irradiation with UV light (254 nm). All the chemicals were
purchased from Sigma–Aldrich.
3.1.1. 7-Chloro-4-ethoxycarbonylmethylene aminoquinoline (II)
A mixture of glycine ethyl ester (0.01 mol) and 4,7-dichloro-
quinoline I (0.01 mol) in absolute ethanol (10 ml) containing
few drops of HCl was reﬂuxed for 2 h to give a creamy white
precipitate which was ﬁltered, washed with cold aqueous
alcohol and recrystallized from absolute alcohol. Yield:
80%; mp: 185–187 C; IR: 3300–1610 cm1; 1H NMR: 1.2
(t, 4H, CH3) 2.4 (s, 2H, CH2) 4.2 (q, 2H, CH2) 6.8–8.5 (m,
5H, aromatic) 9.5 (s, 1H, NH) MS m/z 265. Anal. Calcd
for C13H13N2ClO2: C, 58.9; H, 4.9; N, 10.5. Found: C,
58.72; H. 4.62; N, 10.5%.
3.1.2. 7-Chloro-4-hydrazinocarbonylmethylene aminoquinoline
(III)
A mixture of (0.01 mol) of II and hydrazine hydrate (0.03 mol)
was reﬂuxed in absolute ethanol (10 ml) for 2 h. The solvent
was evaporated under vacuum; the resulting oil was triturated
with ice. The buff precipitate formed, was ﬁltered, washed with
alcohol/water and crystallized from ethanol. Yield: 85%; mp:
195–197 C; IR: 3150–3300 cm1 1650 cm1; 1H NMR: 2.4
(s, 2H, CH2); 6.8–7.8 (m, 5H, aromatic) 8 (s, 2H, NH2) 9–
9.4 (2s, 2H, 2 NH) exchangeable with D2O MS m/z 250. Anal.
Calcd for C11H11N4ClO: C, 52.8; H, 4.3; N, 22.11. Found: C,
52.6; H, 4.58; N, 22.32%.
6NCl
Cl
NCl
NHCH2COOC2H5
I
II
NH2NH2.H2O
NCl
NHCH2CONHNH2
III
CHO
R
R
NCl
NHCH2CONH-N=CH
IV a-f R
R
ClCH2CCI
NCl
N
N
O
O
V
ClCH2COCl CHO
R
R
NCl
N
NO
O
R
VI a-e
'
'
CH3
CH3
'
O
NH2
N = CH
R'
+ NH2CH2COOC2H5
b         Cl      
c          OCH3
d           OCH3
a         B
           R                      R'
r                     H
               H
              H
OH
e        N                       H
f         OH                   H
Scheme 1
62 E.I. Aly3.2. General procedure for the preparation of 7-chloro-4-
(substituted arylidene hydrazinocarbonylmethylene
aminoquinoline (IVa–f)
A mixture of III (0.01 mol) and the appropriate aldehyde
(0.01 mol) in absolute ethanol and drops of glacial acetic acid
was reﬂuxed for 3 h. The precipitate formed was ﬁltered off,
washed with alcohol dried and recrystallized from DMF/water.3.2.1. 4-(p-Bromobenzylidenehydrazinocarbonylmethylene
amino)-7-chloroquinoline (IVa)
Yield: 70%; mp: 198–200 C; IR: 3300–3400 cm1,
1650 cm1; 1H NMR: 2.4 (s, 2H, CH2), 7.2–8.6 (m, 9H, aro-
matic) 9.4 (s, 1H, ald), 11.6–11.8 (2s, 2H, 2 NH) exchange-
able with D2O, MS m/z 416. Anal. Calcd for
C18H14N4BrClO: C, 51.7; H, 3.3; N, 13.4. Found: C, 51.8;
H, 3.16; N, 13.4%.
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chlorobenzylidenehydrazinocarbonylmethylene amino) quinoline
(IVb)
Yield: 65%; mp: 205–207 C; IR: 3200–3400 cm1, 1680 cm1;
1H NMR: 2.4 (s, 2H, CH2) 7.2–8.6 (m, 9H, aromatic) 9.4 (s,
1H, ald), 9.8, 10.2 (2s, 2H, 2 NH) exchangeable with D2O.
Anal. Calcd for C18H14N4Cl2O: C, 58; H, 3.7; N, 16.5. Found:
C, 58.1; H, 3.8; N, 17%.
3.2.3. 7-Chloro-4-(p-
methoxybenzylidenehydrazinocarbonylmethylene amino)
quinoline (IVc)
Yield: 68%; mp: 118–120 C; IR: 3200–3400 cm1, 1600 cm1;
1H NMR: 2.4 (s, 2H, CH2) 4 (s, 3H, OCH3) 7–8.4 (m, 9H, aro-
matic + 1H ald) 11.8 (br, 2H, 2NH) exchangeable with D2O.
Anal. Calcd for C19H17N4ClO2: C, 61.8; H, 4.6; N, 15.1.
Found: C, 61.83; H, 4.59; N, 14.91%.
3.2.4. 7-Chloro-4-(3-hydroxy-4-methoxybenzylidenehydrazino-
carbonyl methylene amino) quinoline (IVd)
Yield: 80%; mp: 190–192 C; IR: 3200–3400–3500 cm1;
1650 cm1; 1H NMR: 2.4 (s, 2H, CH2), 4 (s, 3H, OCH3), 6.8–8.2
(m, 9H, aromatic), 8.8 (s, 1H, ald), 9.9 (s, 1H, OH), 11.8 (br 2H,
2NH) exchangeable with D2O. Anal. Calcd for C19H17N4ClO3:
C, 59.2; H, 4.3; N, 14.5. Found: C, 59.12; H, 4.7; N, 14.9%.
3.2.5. 7-Chloro-4-(p-
dimethylaminobenzylidenehydrazinocarbonyl methylene amino)
quinoline (IVe)
Yield: 80%; mp: 245–247 C; IR: 3200–3400 cm1, 1650 cm1;
1H NMR: 2.4 (s, 2H, CH2), 3.4 (s, 6H, 2CH3) 6.8–8.6 (m, 9H,
aromatic + 1H, ald) 9.8, 12 (2s, 2H, 2 NH) exchangeable with
D2O. Anal. Calcd for C20H20N5ClO: C, 62.9; H, 5.2; N, 18.3.
Found: C, 63; H, 5.2; N, 18.69%.
3.2.6. 7-Chloro-4-(p-hydroxybenzyledenehydrazinocarbonyl-
methylene amino) quinoline (IVf)
Yield: 65%; mp: 173–175 C; IR: 3300–3400 cm1, 1600 cm1;
1H NMR: 2.4 (s, 2H, CH2) 4 (s, 3H, OCH3), 7–8.6 (m, 10H,
aromatic + CH ald) 10 (s, 1H, OH), 11.8 (br, 2H, 2NH)
exchangeable with D2O. Anal. Calcd for C18H15N4ClO2: C,
60.9; H, 4.2; N, 15.7. Found: C, 60.88; H, 4.3; N, 15.41%.
3.3. 4-(4-Amino-2,5-dioxo-1,4-piperazin-1yl)-7 chloroquinoline
(V)
Procedure:An equimolar amount of compound III and chloro-
acetylchloride was reﬂuxed in methylene chloride (30 ml) for
3 h. The resulted buff precipitate was ﬁltered, washed with
aqueous alcohol and crystallized from DMF/water. Yield:
60%; mp: 295–297 C; IR: 1685, 1720 cm1, 3360, 3450 cm1;
1H NMR: 2.4 (s, 4H, 2CH2), 7.9–8.7 (m, 5H, aromatic) 11.4
(s, 2H, NH2). MS/Z 290.5. Anal. Calcd for C13H11N4ClO2:
C, 53.7; H, 3.78; N, 19.2. Found: C, 54.01; H, 4.11; N, 19.44%.
3.4. General procedure for the preparation of 7-chloro-4-[4-
(substituted arylidene imino)] 2,5-dioxo-1-4
piperazinoquinoline (VIa–f)
Method A: Compounds IVa–f (0.1 mol) were reﬂuxed with
chloroacetylchloride (10 ml) in absolute ethanol (10 ml) for4 h. The reﬂuxed mixture was poured into ice/water to produce
compounds VIa–f.
Method B: A mixture of compound V (0.1 mol) and the
appropriate aromatic aldehyde in absolute ethanol (10 ml)
containing few drops of glacial acetic acid was reﬂuxed for
4 h. The solid product was ﬁltered off and recrystallized from
DMF/water.
3.4.1. 4-[4-(4-Bromobenzylideneimino) 2,5-dioxo-1,4-
piperazin-1-yl]-7-chloro quinoline (VIa)
Yield: 75%; mp: 240–242 C; IR: 1610–1620 cm1; 1H NMR:
2.4 (s, 4H, 2CH2) 6.6–8.8 (m, 10H, aromatic + CH ald). Anal.
Calcd for C20H14N4BrClO2: C, 52.4; H, 3.0; N, 12.2. Found:
C, 52.5; H, 2.8; N, 12.25%.
3.4.2. 7-Chloro-4[4-(4-chlorobenzylideneimino)-2,5-dioxo-
1,4[piperazin-1-yl] quinoline (VIb)
Yield: 60%; mp: 295–297 C; IR: 1608–1620 cm1; 1H NMR:
2.4 (s, 4H, 2CH2), 7.5–8.8 (m, 10H, aromatic + CH ald).
Anal. Calcd for C20H14N4Cl2O2: C, 58.25; H, 3.39; N, 13.59.
Found: C, 58.4; H, 3.3; N, 13.93%.
3.4.3. 7-Chloro-4[4-(4-methoxybenzylideneimino)-2,5-dioxo-
1,4[piperazin-1-yl] quinoline (VIc)
Yield: 65%; mp: 275–277 C; IR: 1610–1620 cm1; 1H NMR:
2.4 (s, 4H, 2CH2), 3.8 (s, 3H, OCH3) 7–8.8 (m, 10H, aro-
matic + CH ald) MS/Z 409. Anal. Calcd for C21H17N4ClO3:
C, 61.6; H, 4.16; N, 13.7. Found: C, 61.29, H, 3.79; N, 13.8%.
3.4.4. 7-Chloro-4-[4-(4-hydroxy-3-metoxy-benzylideneimino)
2,5-dioxo-1,4-piperazin-1-yl] quinoline (VId)
Yield: 65%; mp: 246–248 C; IR: 1600–1650 cm1; 1H NMR:
24 (s, 4H, 2CH2) 3.8 (s, 3H, OCH3) 6.9–8.7 (m, 10H, aro-
matic + CH ald) 9.8 (s, 1H, OH) exchangeable with D2O.
MS/Z 423.5. Anal. Calcd for C21H17N4ClO4: C, 59.36; H,
4.0; N, 13.1. Found: C, 59.22; H, 4.11; N, 13.5%.
3.4.5. 7-Chloro-4-[4-(4-dimethylaminobenzylideneimino)-2,5-
dioxo-1,4-piperazin-1-yl] quinoline (VIe)
Yield: 70%; mp: 228–230 C; IR: 1600–1610 cm1; 1H NMR:
2.4 (s, 4H, 2CH2) 3.4 (s, 6H, 2CH3) 6.7–8.5 (m, 10H, aro-
matic + CH ald). Anal. Calcd for C22H20N5ClO2: C, 62.6;
H, 4.7; N, 16.6. Found: C, 62.33; H, 5.33; N, 17%.4. In vitro cytotoxicity
Since breast cells are known to over express EGFR, which
leads to continuous activation of the EGFR pathway involved
in cell proliferation, therefore all the compounds synthesized
were evaluated for their cytotoxicity on breast cancer cell line
MCF-7 using the sulfo-Rho-damine-B stain (SRB) assay using
the method of skehan.25
Cells were plated in 96-multiwall microtiter plate (104 cells/
well) for 24 h before treatment with the compound(s) to allow
attachment of cell to the wall of the plate. Test compounds were
dissolved in DMSO and diluted with saline to the appropriate
volumes. Different concentration of the compound under test
(0.1, 2.5, 5 and 10 lg/ml)were added to the cell monolayer. Trip-
licate wells were prepared for each individual dose. Monolayer
Table 1 In vitro cytotoxic activities of some synthesized
compounds against human breast cancer cell (MCF-7).
Cytotoxicity (IC50)
a,b Compounds
3.097 II
2.84 III
5.37 IVa
8.83 IVc
n.a. V
1.41 VIa
1.5 VIb
2.75 VIc
n.a., no activity.
a IC50, compounds concentration required to inhibit tumor cell
proliferation by 50%.
b Values are averages of three experiments.
Figure 6 Concentration of VIc in lg/ml.
Figure 7 Lapatinib in the ATP binding site of EGFR–TK. With
P
E
with SYBYL version 7.3.
64 E.I. Alycells were incubated with the compound(s) for 48 h at 37 C and
in atmosphere of 5% CO2. After 48 h, cells were ﬁxed, washed
and stained for 30 min with 0.4% (wt/vol) with SRB dissolved
in 1%acetic acid unbounddyewas removedby fourwasheswith
1% acetic acid and attached slain was recovered with Tris
EDTA buffer. Color intensity was measured in an ELISA read-
er. The relation between surviving fraction and drug concentra-
tion is plotted to get the survival curve. Most of the tested
compounds exhibited potent inhibitory activity against MCF-
7 cell line (Table 1 and Figs. 3–6).
5. Molecular modeling study
Docking study was carried out for the target compounds into
EGFR using SYBYL version 7.3. Tripos Inc. with malegro vir-
tual docker program version 2007. The crystal structure of the
enzyme and lapatinib (1XKK) was obtained from protein data
bank PDB26 since it was found that lapatinib mimic ATP and
bind to the ATP binding region of the kinase active site. There-
fore our compounds were modeled by positioning them in the
lapatinib binding site in accordance with the published crystal
structures of quinazoline derivatives bound to kinase.21,27 The
entire complex was then subjected to alternate cycles of mini-
mization and dynamics, the intent was to get a satisfactory
structure for the complex that was consistent with the pub-
lished crystal structure.28,29
From the comparative docking study of our compounds
with many structurally related lead compounds, such as lapat-
inib and geﬁtinib, we could observe how our compounds might
bind to the kinase binding site. Based on a knowledge of the
structure of similar active sites, we docked lapatinib into the
active site of the enzyme (Fig. 7). Docking studies have re-
vealed that lapatinib ring binds to a narrow hydrophobic
pocket in the EGFR–TK domain with three hydrogen bond
interaction with amino acids in vicinity while the aniline moi-
ety lies in a deep and hydrophobic pocket. The bulky sulfa-
moyl group at C-4 of aniline moiety lies at the same position
of the 30-chloro-40-(3-ﬂuorobenzyloxy) moiety of lapatinib
with total interaction energy equal to 71 kcal/mol and
RMSD equal to 0.004 indicating that the ligand was chosen
to interact with the enzyme at the same sites as the main li-equal to 71, RMSD= 0.004 with 3 HB. This picture was created
Figure 8 Compound IVc docked at the ATP binding of EGFR–TK with
P
E equal to 65.3, the ﬁgure shows HB with D 855.
Figure 9 Binding mode of compound VIc in the ATP binding site of EGFR–TK with
P
E equal to 66.3 and showing 2HB with R 841
& C 797.
Molecular modeling based approach, design synthesis and cytotoxic activity 65gand. Compound IVc was then docked in the ATP binding site
of EGFR–TK with total interaction energy equal to
65.3 kcal/mol and showing hydrogen bond with D 855
(Fig. 8). Compound VIc was also docked in the ATP binding
site of EGFR–TK with total interaction energy equal to
66.3 kcal/mol and showing two hydrogen bond with R
841&C 797 (Fig. 9). We can observe that the quinoline ring lies
in a deep and hydrophobic pocket in the EGFR as in case of
the chosen lead compounds with total interaction energy
nearly approaching that of the lead compound lapatinib.
6. Results and discussion
The biological screening results (Table 1) revealed that cytotoxic
activities increase following the conversion of the ester II to the
corresponding acid hydrazide III with IC50 values equal to 3.09
and 2.84 lM, respectively. Converting the acid hydrazide III to
the corresponding arylidene derivatives reduces the cytotoxic
activities as seen from compounds IVa and IVcwhere IC50 were
5.37 and 8.83 lM, respectively. Unfortunately cyclization of
compound III to produce compound V abolishes the activity,which was restored again as seen from compound VIa and VIc
with IC50 1.41 and 2.75 lM, respectively; a result that supports
our hypothesis of designing a hybrid compound bearing three
cytotoxic pharmacophore; herein: 7-chloroquinoline, a pipera-
zine moiety and an azomethine group. It is also clear from the
obtained data that electronic effect of the substituent in the para
position of the arylidene group in the series comprising com-
poundsVIa–e, seems to be an important determinant of activity
since the bromoderivativeVIawasmore active than itsmethoxy
congenere VIc (IC50 equal to 1.41 and 2.75 lM, respectively).
These results indicate a parallel correlation between molecular
modeling study and measurement of potential cytotoxicity as
shown in compounds IVc and VIc with total interaction energy
equal to 65.3 and 66.3 while IC50 equals 8.83 and 2.75,
respectively. We can conclude that the results obtained potenti-
ate the hypothesis of hybrid pharmacophore (compare com-
pounds IVc and VIc).
These preliminary encouraging results of biological screen-
ing of the tested compounds could offer a new pharmacophore
in this ﬁeld that may lead to discovery of a potent antitumor
agent.
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